Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

GEP signatures of primary breast cells radiation treated.

ABSTRACT: Breast cancer (BC) recovery has considerably increased thanks to the advances achieved from research in this field. However, despite the important results obtained, BC remains a complex multifactorial disease with distinct subtypes associated with different outcomes.So, many efforts from radiobiological research are needed to help clinicians in understanding molecular features of a specific tumor subtype, in order to better define the most successful treatment plan, including the choice of the best Radiation Teraphy (RT) modality and schedule in clinical practice. The aim of the present study was to analyze the GEPs in primary breast cancer cells following irradiation with doses of 9 Gy and 23 Gy electron beam delivered by IOERT treatment, in order to define gene signatures of response to high doses of IR.

ORGANISM(S): Homo sapiens

PROVIDER: GSE110933 | GEO | 2021/02/19

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Gene expression profiling induced by electron and proton irradiation in breast cancer cells

Project description:Radiation therapy (RT) remains a vital component of the curative multimodality therapy for many types of cancer including breast cancer (BC) disease. Thus, many efforts from research teams are needed to help clinicians in understanding the molecular portrait of a specific cancer type. Moreover, technological advances in RT are evolving with the use of hadrons, such as protons. However, cell and molecular changes induced by proton exposure are poorly characterized as well as molecular differences induced by high and low Linear Energy Transfer (LET) irradiation modalities, representing a topic of radiobiological interest. We analyze and compare molecular responses, in term of gene expression profile (GEP) changes, induced by conventional and non conventional radiation treatment modalities characterized by different LET values (using electron and proton beams respectively), delivering the same dose of IR, in tumorigenic and non-tumorigenic breast cell lines. We trust that this study could have a role in driving RT towards personalised treatments, evaluating possible combined treatments, based also on the molecular characterization in BC.

2018-12-26 | GSE103472 | GEO

Gene expression profiles proton-induced in brest cell lines

Project description:Literature data report the helpful role of specific molecularly based signatures to predict response to treatment in cancer, including breast cancer (BC) disease. As known, BC is a heterogeneous disease presenting distinct subtypes with different clinical outcomes. Thus, the choice of a unique treatment plan for all BC patients, including radiation therapy (RT), may be not the best option. Technological advances in RT are evolving with the use of proton beams, which reduce the dose administered to the heart compared to conventional RT. However, limitate data regarding proton-induced molecular changes are currently available. The aim of this study was therefore to study gene expression profiles induced by proton irradiation with 0.5, 2 and 9 Gy of Ionizing radiation (IR) doses in breast cells. The great amount of data here collected, represent an useful tool to better understand the molecular mechanisms elicited by proton irradiation, thereby filling the existing lack of data in the literature.

2019-07-29 | GSE116325 | GEO

Comparison study of two different treatment positions in patients receiving pelvic radiation for gynecologic cancer.

Project description:Intervention1: Radiation in prone position using Belly Board device: Comercially available device used to treat patients in prone position who are undergoing external beam pelvic radiation.Patients lie prone on the device during treatment.External beam radiation of 40-45 Gy in 1.8-2 Gy per fraction,one fraction daily,5 days a week, for 4-5 week duration. Control Intervention1: Radiation in supine position: External beam radiation in supine position.External beam radiation of 40-45 Gy in 1.8-2 Gy per fraction,one fraction daily,5 days a week,for 4-5 week duration.

| 2574599 | ecrin-mdr-crc

Transcription profiling by array to investigate the effect of combined external beam radiotherapy (photon or carbon) and 131I-Cetuximab endoradiotherapy in A431 xenograft tumors in mice

Project description:Subcutaneous A431 tumors in the right hind limb of NCr nu/nu mice were treated with 5 daily fractions of external beam radiotherapy (2 Gy photon or 1 Gy carbon per fraction), a single fraction of 7.2 MBq 131Iodine-labelled Cetuximab intravenously or a combination of the two. Untreated tumors served as controls. Mice were sacrificed and tumor tissue collected for expression profiling 5 days after endoradiotherapy of 1 week after the last fraction of external beam radiotherapy.

2023-12-08 | E-MTAB-6515 | biostudies-arrayexpress

Combined external beam radiotherapy (photon or carbon) and 131I-MIP-1145 (benzamide) endoradiotherapy in syngeneic B16F10 mouse tumor model

Project description:Subcutaneous B16F10 tumors in the right hind limb of C57BL/6 mice were treated with 5 daily fractions of external beam radiotherapy (8 Gy photon or 5 Gy carbon per fraction), a single fraction of 13.3 MBq 131Iodine-labelled benzamide-derivative MIP-1145 intravenously or a combination of the two. Untreated tumors served as controls. Mice were sacrificed and tumor tissue collected for expression profiling 5 days after endoradiotherapy of 1 week after the last fraction of external beam radiotherapy.

2023-12-08 | E-MTAB-6514 | biostudies-arrayexpress

caArray_geral-00143: An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen

Project description:Clinical heterogeneity of esrtrogen receptor-negative, progesterone receptor-negative [ER(-)/PR(-)] breast cancer (BC) suggests biological heterogeneity. We performed gene expression analysis of primary BCs and BC cell lines to identify the underlying biology of ER(-)/PR(-) disease, define subsets, and identify potential therapeutic targets. geral-00143 Assay Type: Gene Expression Provider: Affymetrix Array Designs: HG-U133A Organism: Homo sapiens (ncbitax) Material Types: cRNA, cell, OrganismPart, whole_organism, total_RNA Disease States: breast carcinomas

2015-05-15 | E-GEOD-68892 | biostudies-arrayexpress

caArray_geral-00143: An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen

2015-05-15 | GSE68892 | GEO

Gene expression profiling in response to radiation treatment in human breast cancer

Project description:Treatment-related morbidities have been linked to the large post-operative treatment volumes required for external beam partial breast irradiation (PBI). Alternative PBI techniques require equipment that is not readily available. To address these issues, we designed a phase I trial utilizing widely available technology to 1) evaluate the safety of a single radiation treatment delivered preoperatively to the small-volume, intact breast tumor and 2) identify imaging and genomic markers of radiation response. Women 55 or older with clinically node negative, ER+ and/or PR+, HER2-, T1 invasive carcinomas or low-intermediate grade in situ disease â¤2cm were enrolled (n=32). Intensity-modulated radiotherapy was used to deliver 15 Gy (n=8, patients 01-08), 18 Gy (n=8, patients 09-16), or 21Gy (n=16, patients 17-32) to the tumor with a 1.5cm margin. Lumpectomy was performed within 10 days. Paired pre- and post-radiation MRI images and patient tumor samples were analyzed.

2015-10-31 | E-GEOD-65505 | biostudies-arrayexpress

transcriptomic assay on embryos after barley seeds gamma_irradiation-Molecular mechanisms of growth stimulation after low-dose irradiation of barley seeds

Project description:4plex_barley_2017_01 - transcriptomic assay on embryos after barley seeds gamma_irradiation - Why radiation exposure on seeds at low doses causes stimulation of plant growth after germination? - Barley dry seeds of variety “Nur” were irradiated by gamma-rays (Co-60) at doses 20 Gy (stimulatory) and 100 Gy (inhibitory). Immediately after irradiation we put seeds for germination to Petri dishes containing water filter paper; embryos were taken 2h after irradiation, embryos with embrionic roots were taken 24 and 48h after irradiation. The following comparisons have been made: non-irradiated (0 Gy), 2h vs. 20 Gy, 2h; 0 Gy, 24h vs. 20 Gy, 24h; 0 Gy, 48h vs. 20 Gy, 48h; 0 Gy, 24h vs. 100 Gy, 24h. Three independent biological replicates were used.

2019-12-01 | GSE117356 | GEO

Gene expression profiles of primary tumors with radiotherapy and lung metastases in mouse squamous cell carcinoma model.

Project description:To examine whether the local carbon ion radiotherapy affects the characteristics of the metastatic tumors, the expression profiles of the primary tumors and the lung metastases were studied in a mouse squamous cell carcinoma model by applying local radiotherapy with no irradiation (negative control), gamma-ray irradiation (reference beam), and carbon-ion irradiation. Keywords: mouse, squamous cell carcinoma, primary tumor, lung metastases, radiotherapy, carbon ion, gamma ray A highly metastatic mouse squamous cell carcinoma NR-S1 was implanted into the hind leg of synergetic C3H/HeNrs mice and irradiated with 5 Gy of carbon ion beam. 8 Gy of gamma ray was used as a reference beam. At 2 weeks after the irradiation, the lung tissue was sampled. In order to collect samples of primary tumors, the tumors were implanted in other mice and irradiated in the same manner, and the primary tumors were collected at 1 week after the irradiation. The tumor cells of the primary and metastatic tumors were collected by laser microdissection, and oligonucleotide microarray analysis of the irradiated primary tumors and the metastatic tumors were all performed in comparison to the non-irradiated primary tumor by two-color methods.

2009-04-22 | E-GEOD-9305 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data